Noninvasive management of infants with SFTPC pathogenic variants

Funding

The authors wish to acknowledge Dr. Lawrence Nogee for his additional expertise in SFTPC pathogenic variants. DRL has funding from the National Institute of Health UG1OD024952. MDM reports grant support from the National Institute of Environmental Health Sciences (NIEHS) P30ES001247, K08ES033290, and Boehringer Ingelheim (BI) as a scientific advisory committee member for childhood interstitial lung disease. JAW reports grant support from the National Heart, Lung and Blood Institute (R01 HL149853, U01 HL134745) and the Children's Discovery Institute. TS reports no funding or conflicts of interest. RRD reports the following: -Now Vitals, CEO and Founder. -Boehringer Ingelheim, Consultant and Coordinating Investigator. -Earables, Founder and Chief Medical Officer. -EvoEndo, Consultant and Founder. -Roche, Inc., Consultant. -The France Foundation, Consultant. Now Vitals, CEO and Founder. Boehringer Ingelheim, Consultant and Coordinating Investigator. Earables, Founder and Chief Medical Officer. EvoEndo, Consultant and Founder. Roche, Inc., Consultant. The France Foundation, Consultant. The authors wish to acknowledge Dr. Lawrence Nogee for his additional expertise in pathogenic variants. DRL has funding from the National Institute of Health UG1OD024952. MDM reports grant support from the National Institute of Environmental Health Sciences (NIEHS) P30ES001247, K08ES033290, and Boehringer Ingelheim (BI) as a scientific advisory committee member for childhood interstitial lung disease. JAW reports grant support from the National Heart, Lung and Blood Institute (R01 HL149853, U01 HL134745) and the Children's Discovery Institute. TS reports no funding or conflicts of interest. RRD reports the following: ‐ SFTPC